These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31121484)

  • 1. SNHG14 confers gefitinib resistance in non-small cell lung cancer by up-regulating ABCB1 via sponging miR-206-3p.
    Wu K; Li J; Qi Y; Zhang C; Zhu D; Liu D; Zhao S
    Biomed Pharmacother; 2019 Aug; 116():108995. PubMed ID: 31121484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q; Wang Y; He J
    J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P; Hou J; Yao M; Wu J; Ren G
    Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
    Ma G; Zhu J; Liu F; Yang Y
    DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.
    Li X; Zhang X; Yang C; Cui S; Shen Q; Xu S
    Cell Cycle; 2018; 17(14):1772-1783. PubMed ID: 30010468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
    Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
    Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing.
    Liu J; Wang W; Wang K; Liu W; Zhao Y; Han X; Wang L; Jiang BH
    J Transl Med; 2024 Aug; 22(1):793. PubMed ID: 39198847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
    Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
    J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.
    Tang Q; Zhou Q; Li J; Yang X; Wang R; Wang X; Xu M; Han L; Wu W; Wang S
    Carcinogenesis; 2023 Aug; 44(6):497-510. PubMed ID: 37144780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy.
    Xiao Y; Yin C; Wang Y; Lv H; Wang W; Huang Y; Perez-Losada J; Snijders AM; Mao JH; Zhang P
    Mol Oncol; 2018 Jun; 12(6):883-895. PubMed ID: 29633504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-135a Confers Resistance to Gefitinib in Non-Small Cell Lung Cancer Cells by Upregulation of RAC1.
    Zhang T; Wang N
    Oncol Res; 2018 Sep; 26(8):1191-1200. PubMed ID: 29386087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.
    Yang T; Li H; Chen T; Ren H; Shi P; Chen M
    Mol Cells; 2019 Mar; 42(3):270-283. PubMed ID: 30841025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
    Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
    BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
    Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
    J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsa-miR-4271 downregulates the expression of constitutive androstane receptor and enhances in vivo the sensitivity of non-small cell lung cancer to gefitinib.
    Wang C; Ding S; Sun B; Shen L; Xiao L; Han Z; Huang H
    Pharmacol Res; 2020 Nov; 161():105110. PubMed ID: 32755614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer.
    Zhang Y; Qian J; Fu Y; Wang Z; Hu W; Zhang J; Wang Y; Guo Y; Chen W; Zhang Y; Wang X; Xie Z; Ye H; Ye F; Zuo Z
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167447. PubMed ID: 39089636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.